drug

(alogliptin benzoate + metformin hydrochloride)

Marketedupdated 2mo ago

by Takeda Pharmaceuticals USA Inc

Approved

community read0 votes

indications

investigational

Type 2 Diabetes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

Data sources

ClinicalTrials.gov

last refreshed 1m ago

Found something off?

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Jul 27, 2026

20 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (4)

May 24, 2029formulationUS 89006382.9y
May 24, 2029formulationUS 89006382.9y
Jun 27, 2028compositionUS 78076892.0y
Jun 27, 2028compositionUS 78076892.0y

FDA exclusivities (2)

Jul 27, 2026M-300Method (3y)20d
Jul 27, 2026M-300Method (3y)20d